Literature DB >> 3279015

Cephalosporinase interactions and antimicrobial activity of BMY-28142, ceftazidime and cefotaxime.

M Hiraoka1, S Masuyoshi, S Mitsuhashi, K Tomatsu, M Inoue.   

Abstract

Cephalosporinases of Enterobacter cloacae and Citrobacter freundii were responsible for resistance to newer cephalosporins such as cefotaxime and ceftazidime but not BMY-28142. Interaction of these cephalosporins including hydrolysis, binding, inhibition, and inactivation with cephalosporinases from E. cloacae GN7471 and C. freundii GN7391 were studied. BMY-28142 was much more stable against the both enzymes than cephalothin, but more hydrolyzable than cefotaxime and ceftazidime at higher concentration such as 100 microM. Because of low affinity for the enzymes, i.e. large Km and Ki, the calculated hydrolysis rate of BMY-28142 at 0.1 microM was smaller than those of cefotaxime and ceftazidime, that explained the difference in activity against cephalosporinase-producing strains between BMY-28142 and cefotaxime or ceftazidime. The effects of cephalosporinase production on susceptibility of Escherichia coli omp mutants were examined using a plasmid having cephalosporinase gene of C. freundii GN346. Decrease in susceptibility of E. coli by cephalosporinase production was larger in the strain lacking outer membrane proteins (Omp) F and C, and smaller in the strain producing OmpF constitutively.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3279015     DOI: 10.7164/antibiotics.41.86

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  17 in total

1.  Plasmid-encoded metallo-beta-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem.

Authors:  H Yano; A Kuga; R Okamoto; H Kitasato; T Kobayashi; M Inoue
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  In vitro and in vivo activities of DQ-2556 and its mode of action.

Authors:  M Tanaka; M Otsuki; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

3.  Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents.

Authors:  H Nikaido; W Liu; E Y Rosenberg
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

4.  Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins.

Authors:  J C Fung-Tomc; E Gradelski; E Huczko; T J Dougherty; R E Kessler; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 5.  A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Authors:  K Bush; G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

6.  Reevaluation of the factors involved in the efficacy of new beta-lactams against Enterobacter cloacae.

Authors:  F Bellido; J C Pechère; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

Review 7.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

8.  Transferable imipenem resistance in Pseudomonas aeruginosa.

Authors:  M Watanabe; S Iyobe; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

9.  Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329.

Authors:  M J Pucci; J Boice-Sowek; R E Kessler; T J Dougherty
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 10.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.